A partnership between UC Davis Comprehensive Cancer Center, TargaGenix, and Northeastern University will receive nearly $3 million over five years to study pancreatic ductal adenocarcinoma through an NIH R01 grant.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe